Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rangaswamy Govindarajan

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
167
0.860
Why?
Anus Neoplasms
1
2018
34
0.670
Why?
Bone Marrow Neoplasms
1
2015
15
0.570
Why?
Embolism
1
2015
27
0.570
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1052
0.570
Why?
Gene Regulatory Networks
1
2016
127
0.550
Why?
Tumor Lysis Syndrome
1
2014
6
0.540
Why?
Carcinoma, Squamous Cell
1
2018
395
0.520
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
71
0.510
Why?
Neoplasm Recurrence, Local
1
2018
629
0.500
Why?
Pyrazoles
1
2014
116
0.500
Why?
Pyrimidines
1
2014
208
0.470
Why?
Biliary Tract Diseases
1
2012
12
0.460
Why?
Actinomycosis
1
2012
10
0.460
Why?
Angiogenesis Inhibitors
2
2006
210
0.460
Why?
Salvage Therapy
1
2013
147
0.460
Why?
Stomach Neoplasms
1
2015
174
0.450
Why?
Bile Duct Neoplasms
1
2012
30
0.450
Why?
Clinical Trials as Topic
5
2019
503
0.450
Why?
Benzenesulfonates
2
2011
12
0.410
Why?
Prognosis
6
2019
2139
0.400
Why?
Gene Expression Profiling
1
2016
1146
0.400
Why?
Carcinoma, Hepatocellular
1
2013
201
0.400
Why?
Middle Aged
12
2020
13645
0.380
Why?
Stroke
1
2015
548
0.380
Why?
Pyridines
2
2011
133
0.370
Why?
Colorectal Neoplasms
2
2003
237
0.360
Why?
Liver Neoplasms
1
2013
351
0.360
Why?
Drug Industry
1
2007
41
0.310
Why?
Aged, 80 and over
6
2018
3607
0.310
Why?
Heparin
1
2007
101
0.310
Why?
Hypertensive Encephalopathy
1
2006
4
0.310
Why?
raf Kinases
1
2006
5
0.310
Why?
Communication Barriers
1
2007
39
0.310
Why?
Thrombocytopenia
1
2007
101
0.300
Why?
Thiazolidinediones
1
2007
105
0.300
Why?
Aged
9
2020
10473
0.270
Why?
Anticoagulants
1
2007
288
0.260
Why?
Thrombosis
1
2007
268
0.260
Why?
Skin
1
2007
470
0.250
Why?
Adult
9
2020
14634
0.250
Why?
Enzyme Inhibitors
1
2006
455
0.250
Why?
Female
11
2020
29374
0.240
Why?
Survival Rate
2
2018
1008
0.230
Why?
Prostatic Neoplasms
1
2007
426
0.230
Why?
Camptothecin
1
2002
17
0.220
Why?
Humans
16
2020
54858
0.220
Why?
Follow-Up Studies
3
2019
2460
0.220
Why?
Antineoplastic Agents, Phytogenic
1
2002
88
0.210
Why?
Male
10
2020
28269
0.210
Why?
Diabetes Mellitus, Type 2
1
2007
483
0.210
Why?
Lung Neoplasms
1
2007
615
0.200
Why?
Oximes
1
2020
12
0.200
Why?
Pyrimidinones
1
2020
19
0.200
Why?
Pyridones
1
2020
42
0.200
Why?
Thalidomide
1
2002
396
0.180
Why?
Imidazoles
1
2020
147
0.180
Why?
Cholangiocarcinoma
2
2011
27
0.180
Why?
Protein Kinase Inhibitors
1
2020
222
0.170
Why?
Survival Analysis
3
2020
776
0.160
Why?
Antineoplastic Agents
2
2019
1299
0.150
Why?
Melanoma
1
2020
329
0.150
Why?
Neoplasm Staging
2
2013
812
0.140
Why?
Combined Modality Therapy
1
2018
697
0.140
Why?
Severity of Illness Index
1
2019
1127
0.140
Why?
Gene Amplification
1
2015
57
0.130
Why?
Polycomb Repressive Complex 2
1
2015
50
0.130
Why?
Genes, myc
1
2015
44
0.130
Why?
Adenine
1
2014
46
0.130
Why?
Antibodies, Monoclonal
1
2019
572
0.130
Why?
Retrospective Studies
3
2018
6462
0.130
Why?
Skin Neoplasms
1
2020
567
0.130
Why?
Piperidines
1
2014
104
0.130
Why?
United States
3
2019
5253
0.120
Why?
Gene Deletion
1
2015
293
0.120
Why?
Registries
3
2007
574
0.120
Why?
Quinazolines
1
2013
39
0.120
Why?
Leukemia, Myeloid, Acute
1
2015
182
0.120
Why?
Actinomyces
1
2012
9
0.120
Why?
Treatment Outcome
4
2020
5803
0.110
Why?
Endoscopy, Gastrointestinal
1
2012
80
0.110
Why?
Gallbladder Neoplasms
1
2011
6
0.110
Why?
Gene Expression Regulation, Neoplastic
1
2016
892
0.110
Why?
Comorbidity
2
2019
699
0.100
Why?
Phenylurea Compounds
2
2011
15
0.100
Why?
Antibodies, Monoclonal, Humanized
1
2013
244
0.100
Why?
Niacinamide
2
2011
25
0.100
Why?
Incidence
2
2019
1116
0.100
Why?
Neoplasms
1
2019
1306
0.090
Why?
Causality
1
2007
50
0.080
Why?
Drugs, Investigational
1
2007
19
0.080
Why?
Necrosis
1
2007
205
0.080
Why?
Hospitals, University
1
2007
98
0.080
Why?
Confidence Intervals
1
2007
173
0.080
Why?
United States Food and Drug Administration
1
2007
98
0.080
Why?
Neoplasm Metastasis
2
2011
260
0.080
Why?
Probability
1
2007
184
0.080
Why?
Age Distribution
1
2007
214
0.080
Why?
Tomography, X-Ray Computed
1
2012
1274
0.070
Why?
Medical Oncology
1
2007
106
0.070
Why?
Anti-Bacterial Agents
1
2012
825
0.070
Why?
Syndrome
1
2006
260
0.070
Why?
Patient Selection
1
2007
298
0.070
Why?
Publication Bias
1
2005
14
0.070
Why?
Editorial Policies
1
2005
12
0.070
Why?
Periodicals as Topic
1
2005
69
0.060
Why?
Dose-Response Relationship, Drug
1
2007
1537
0.060
Why?
Risk Assessment
1
2007
1416
0.050
Why?
MAP Kinase Kinase Kinases
1
2020
19
0.050
Why?
Socioeconomic Factors
1
2003
640
0.050
Why?
Proto-Oncogene Proteins B-raf
1
2020
91
0.050
Why?
Mutation, Missense
1
2020
116
0.050
Why?
Trisaccharides
1
2019
1
0.050
Why?
Premedication
1
2019
18
0.050
Why?
Drug Administration Schedule
1
2020
418
0.050
Why?
Administration, Oral
1
2020
478
0.040
Why?
Infusions, Intravenous
1
2019
241
0.040
Why?
Antibodies
1
2019
173
0.040
Why?
Magnetic Resonance Imaging
1
2006
1699
0.040
Why?
Health Services Accessibility
1
2003
444
0.040
Why?
Disease Management
1
2019
198
0.040
Why?
Arkansas
1
2003
2231
0.040
Why?
Adolescent
1
2007
7022
0.030
Why?
In Situ Hybridization, Fluorescence
1
2015
272
0.030
Why?
Polymorphism, Single Nucleotide
1
2015
569
0.030
Why?
Young Adult
1
2020
4437
0.020
Why?
Disease-Free Survival
1
2011
507
0.020
Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description